Here’s a link to our blog post on ARA 290:
^ It contains much more than the information below. Including my personal review, dosing, purchasing and more.
An ideal peptide to Stack with ARA 290 is TB4 Frag
See: TB4‑Frag’s Edge on Tissue Healing – for all ages & stages!
Research (from Limitless website)
ARA-290 is an 11-amino acid synthetic peptide derived from erythropoietin’s helix-B domain that produces tissue-protective effects without stimulating blood cell production.
Laboratory research focuses on its activation of the innate repair receptor pathway across multiple research applications.
Neural Protection and Pain Research
ARA-290 targets spinal cord microglia in laboratory models, producing dose-dependent relief of mechanical and cold allodynia that persists for extended periods.
The peptide suppresses spinal microglia activation and prevents spreading inflammatory responses in nerve injury studies[1].
Research shows ARA-290 promotes nerve regeneration and remyelination in autoimmune neuritis models[2].
Studies indicate the peptide increases corneal nerve fiber density in laboratory applications investigating small fiber neuropathy[3].
Cardiovascular Research
Laboratory investigations reveal ARA-290 enhances endothelial progenitor cell-mediated vascular repair in retinal ischemia models.
The peptide reduces neovascular pathology while supporting balanced vascular restoration processes.
Research applications include myocardial protection studies where ARA-290 shows improved survival rates following myocardial infarction.
Radiolabeled versions enable cardiac imaging applications targeting ischemic tissue regions[4].
In burn injury research, ARA-290 prevents secondary microvascular thrombosis and maintains microvasculature patency.
Laboratory studies confirm the peptide mitigates innate inflammatory responses in thermal injury models[5].
Metabolic Research Applications
Diabetes research applications show ARA-290 produces sustained improvements in hemoglobin A1c levels and lipid profiles in laboratory studies[6].
These metabolic changes occur alongside improvements in neuropathic symptoms in research models[3].
Laboratory investigations reveal ARA-290 protects pancreatic islets from cytokine-induced apoptosis.
This cytoprotective mechanism occurs through innate repair receptor activation pathways.
Autoimmune and Inflammatory Research
Studies in lupus models show ARA-290 provides comprehensive protection from disease development through anti-inflammatory and tissue protection mechanisms.
The peptide’s non-erythrogenic properties make it suitable for autoimmune research applications[7].
Research confirms ARA-290 improves recovery in experimental autoimmune neuritis while suppressing peripheral nerve inflammation.
Laboratory studies focus on the peptide’s immunomodulatory capabilities without hematopoietic effects[2].
Renal Protection Research
Kidney research applications investigate ARA-290’s role as a nephroprotective agent in ischemia-reperfusion injury scenarios.
Laboratory studies show the peptide attenuates renal injury without thrombotic complications[8].
Research focuses on ARA-290’s activation of tissue repair pathways that promote healing while preventing excessive inflammatory responses.
Studies investigate applications for acute kidney injury models[8].
References
- M. Swartjes et al., “ARA 290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-Term Relief of Neuropathic Pain Coupled with Suppression of the Spinal Microglia Response,” SAGE Publications, Jan. 2014. doi: 10.1186/1744-8069-10-13. https://doi.org/10.1186/1744-8069-10-13
- Y. Liu et al., “Erythropoietin-Derived Nonerythropoietic Peptide Ameliorates Experimental Autoimmune Neuritis by Inflammation Suppression and Tissue Protection,” Public Library of Science (PLoS), Mar. 2014. doi: 10.1371/journal.pone.0090942. https://doi.org/10.1371/journal.pone.0090942
- A. Dahan et al., “ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density,” Springer Science and Business Media LLC, Jan. 2013. doi: 10.2119/molmed.2013.00122. https://doi.org/10.2119/molmed.2013.00122
- N. Mohtavinejad, M. Hajiramezanali, M. Akhlaghi, A. Bitarafan-rajabi, and N. Gholipour, “Synthesis and evaluation of 99mTc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region,” Iranian Journal of Basic Medical Sciences, vol. 24, pp. 1488–1499, 2021.
- S. Bohr et al., “Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns,” Proceedings of the National Academy of Sciences, Feb. 2013. doi: 10.1073/pnas.1214099110. https://doi.org/10.1073/pnas.1214099110
- M. Brines et al., “ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes,” Springer Science and Business Media LLC, Jan. 2014. doi: 10.2119/molmed.2014.00215. https://doi.org/10.2119/molmed.2014.00215
- B. Huang et al., “Non‐erythropoietic erythropoietin‐derived peptide protects mice from systemic lupus erythematosus,” Wiley, Mar. 2018. doi: 10.1111/jcmm.13608. https://doi.org/10.1111/jcmm.13608
- W. G. van Rijt et al., “ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury,” Springer Science and Business Media LLC, Jan. 2013. doi: 10.1186/1479-5876-11-9. https://doi.org/10.1186/1479-5876-11-9
Diary of Recovery 